利拉鲁肽对2型糖尿病心血管事件和全因死亡率的影响  

Effect of liraglutide on cardiovascular events and all-cause mortality in type 2 diabete mellitus

作　　者：封东来[1] 魏东[1] 李芳[1] 梁斌[1] FENG Donglai;WEI Dong;LI Fang;LIANG Bin(Department of Endocrinology and Metabolism,Chengdu Second People′s Hospital,Chengdu 610021,China)

机构地区：[1]成都市第二人民医院内分泌代谢科

出　　处：《新疆医科大学学报》2019年第9期1156-1158,1162,共4页Journal of Xinjiang Medical University

基　　金：四川省科技支撑计划项目(16PJ0301)

摘　　要：目的探讨利拉鲁肽对2型糖尿病患者心血管事件的发生和全因死亡率的影响。方法选取成都市第二人民医院2018年1-3月符合纳入标准的2型糖尿病患者200例,随机分为对照组(n=100)和利拉鲁肽组(n=100)。对照组给予饮食、运动治疗,三餐前皮下注射门冬胰岛素,睡前皮下注射甘精胰岛素;利拉鲁肽组在对照组基础上注射利拉鲁肽,起始剂量为0.6 mg/d,加量为1.2 mg/d,连续治疗6个月。治疗结束后随访36个月,记录患者心血管不良事件和全因死亡事件发生的例数及时间等,绘制Kaplan-Meier生存曲线。结果 2组患者常规用药情况差异无统计学意义,具有可比性;利拉鲁肽组不良心血管事件发生率显著低于对照组(P<0.05);利拉鲁肽组全因死亡率低于对照组,但差异无统计学意义(P>0.05);利拉鲁肽组患者生存情况明显优于对照组。结论利拉鲁肽可降低2型糖尿病心血管事件和全因死亡率。Objective To investigate the effects of liraglutide on cardiovascular events and all-cause mortality in patients with type 2 diabetes mellitus. Methods A total of 200 patients with type 2 diabetes who met the inclusion criteria from January to March 2016 were randomly divided into control group(n=100) and liraglutide group(n=100). The control group was given diet, exercise therapy, subcutaneous injection with insulin aspart and subcutaneous injection with insulin glargine before meals, and liraglutide group was injected with liraglutide at the initial dose of 0.6 mg/d. The dosage was 1.2 mg/d and continuous treatment for 6 months. After the treatment, the patients were followed up for 36 months. The number and time of cardiovascular adverse events and all-cause deaths were recorded, and the K-M survival curve was drawn. Results There were no differences in the types of conventional medications between the two groups. The incidence of adverse cardiovascular events was significantly lower in the liraglutide group than in the control group(P<0.05). The all-cause mortality in the liraglutide group was lower than that in the control group. However, the difference was not statistically significant(P>0.05);the survival curve of the liraglutide group was superior to the control group. Conclusion Liraglutide reduces cardiovascular events and all-cause mortality in type 2 diabetes mellitus.

关 键 词：利拉鲁肽 2型糖尿病 心血管事件 全因死亡 

分 类 号：R453.9[医药卫生—治疗学]